Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

A technology for diseases and airway diseases, applied in the direction of disease diagnosis, botany equipment and methods, biochemical equipment and methods, etc.

Inactive Publication Date: 2012-04-04
CANCER PREVENTION & CURE
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Further, there are no blood tests available today that can detect only the presence of specific lung histopathological states

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
  • Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
  • Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0372] Human blood samples were collected from volunteers. Thirty samples were collected from individuals not known to have non-small cell lung cancer or asthma. These 30 samples comprise and are referred to herein as the "normal population". Twenty-eight blood samples were collected from individuals known to have asthma and diagnosed as such by a physician. These 28 samples comprise and are referred to herein as the "Asthma Population". Thirty blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed as such by a physician. These 30 samples comprise and are referred to herein as the "Lung Cancer Population".

[0373]Studies are performed to select biomarkers whose altered expression levels are believed to be associated with lung cancer or asthma. As used herein, "lung cancer" is intended to include those lung cancers known as non-small cell lung cancer. The following 59 biomarkers were selected for testing: CD40, hepatic growth ...

Embodiment 2

[0387] Human blood samples were collected from volunteers. 142 samples were collected from individuals not known to have non-small cell lung cancer or asthma. These samples comprise and are referred to herein as "normal populations". 108 blood samples were collected from individuals known to have asthma and diagnosed as such by a physician. These samples comprise and are referred to herein as the "Asthma population". 146 blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed as such by a physician. These samples comprise and are referred to herein as the "lung cancer population".

[0388] The same procedure as described in Example 1 was carried out. Figures 2A-2E The obtained results are shown. These results provide guidance for selecting appropriate biomarkers for use in the methods of the invention. In particular, probability values ​​for specific markers are useful at this point.

[0389] Figure 2EProbabilities associa...

Embodiment 3

[0391] Human blood samples were collected from volunteers. 288 samples were collected from individuals not known to have non-small cell lung cancer or asthma. These samples comprise and are referred to herein as "normal populations". 180 blood samples were collected from individuals known to have asthma and diagnosed as such by a physician. These samples comprise and are referred to herein as the "Asthma population". 360 blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed as such by a physician. These samples comprise and are referred to herein as the "lung cancer population".

[0392] The same procedure as described in Example 1 was carried out. Panomics' Procarta Cytokine kit (Cat# PC1017) was also used. Antibodies to PAI-1 and leptin from two different kits were used. PAI-1 A and leptin 1 The antibody was produced by Millipore. PAI-1 B The antibody was produced by Panomics. Figures 3A-3E Display the obtained resul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subjects response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Description

Background of the invention [0001] (a) Field of Invention [0002] The present invention relates to the detection, identification, evaluation, prevention, diagnosis and treatment of lung diseases using biomarkers and kits thereof. More specifically, the present invention relates to the diagnosis of non-small cell carcinoma and reactive airway disease by measuring and quantifying the expression levels of specific markers. The present invention also relates to the identification of biomarkers present in human serum or other biological fluids that are found to be expressed at levels different from those found in normal populations, suggesting association with human lung tissue and the human respiratory system Pathology. By identifying markers associated with these pathological conditions, quantifying the expression levels of these biomarkers, and comparing the expression levels to those normally expected to be present in normal human serum, it is possible to detect them early i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/12G01N33/53
CPCG01N33/57423G01N2800/12G01N33/6893G01N2333/96494G01N2800/60G01N2800/52
Inventor R·T·斯特里佩E·伊兹比卡S·H·贝克
Owner CANCER PREVENTION & CURE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com